Skip to main content
SpringerLink
Log in

Valproic acid inhibits cell size and cell proliferation by AMPK-mediated mTOR signaling pathway in JEG-3 cells

  • Original Article
  • Published:
BioChip Journal Aims and scope Submit manuscript

Abstract

Valproic acid is commonly used to treat seizure disorders, bipolar disorder, migraine prophylaxis, and neuropathic pain. Despite its effectiveness and widespread use, valproic acid has been proven to exert considerable teratogenic potential, such as neural tube defects and malformations of the heart in both the humans and animals. However, the molecular mechanism of the teratogenic effects of valproic acid has not been fully elucidated. Because adverse effects in fetus by teratogens are obviously detectable only after birth and there are the limits of teratogenicity testing using rodents, such as thalidomide tragedy, new strategies for pre-determining teratogenic effects are required. Here, we try to elucidate the indirect teratogenicity of valproic acid in a human placenta-derived cell line (JEG-3) using a transcriptomic approach. In this study, using human whole genome oligonucleotide microarray, we identified 2,076 up- and 1,730 down-regulated genes which were changed more than 1.5-fold in JEG-3 cells exposed to valproic acid. Many of these genes have associations with lysosome, transport, tight junction, splicesome, cell cycle and mammalian target of rapamycin (mTOR)-signaling pathway. Among these, we focused on the adenosine monophosphate (AMP)-dependent kinase or AMP-activated kinase (AMPK)-mediated mTOR signaling pathway, and hypothesized that the negative control of mTOR signaling by AMPK might induce inhibition of the growth of JEG-3 cell exposed to valproic acid. First, flow cytometry analysis showed that valproic acid induced the inhibition of cell growth caused by G1 phase arrest. Second, the expression of genes related to mTOR signaling was changed. Using quantitative real-time RT-PCR data, it was confirmed that PTEN, PIK3CB, PIK3CD, PIK3R3, IRS2, and PRKAA2 (AMPKα2) were overexpressed, and that GβL and AKT1 were under-expressed in valproic acid treated JEG-3 cells compared to a control. We also confirmed the protein expression and the activation of AMPK and raptor after valproic acid exposure. Thus, this study suggests that valproic acid affects AMPK, and then AMPK may influence cell growth through mTOR signaling, and particularly, mTOR activity is suppressed by raptor activation. From this point of view, these genes may provide potential biomarkers that may contribute to decrease the number of candidate drugs showing teratogenicity in large-scale tests using placenta cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ehrenstein, V., Sorensen, H.T., Bakketeig, L.S. & Pedersen, L. Medical databases in studies of drug teratogenicity: methodological issues. Clin. Epidemiol. 2, 37–43 (2010).

    Google Scholar 

  2. Ward, R.M. Maternal-placental-fetal unit unique problems of pharmacologic study. Pediatr. Clin. North Am. 36, 1075–1088 (1989).

    CAS  Google Scholar 

  3. Lenz, W. Thalidomide and congenital abnormalities. Lancer. 1, 45 (1962).

    Article  Google Scholar 

  4. Schwarz, E.B. et al. Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res. A. Clin. Mol. Teratol. 85, 858–863 (2009).

    Article  CAS  Google Scholar 

  5. Lee, S.H. et al. Effects of zinc oxide nanoparticles on gene expression profile in human keratinocytes. Mol. Cell. Toxicol. 8, 113–118 (2012).

    Article  CAS  Google Scholar 

  6. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A. & Ahr, H.J. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637, 23–39 (2008).

    Article  CAS  Google Scholar 

  7. Kim, Y.R. et al. Gene expression profiles of human lung epithelial cells exposed to toluene. Toxicol. Environ. Health Sci. 4, 269–276 (2012).

    Article  Google Scholar 

  8. Chen, F. Induction of oxidative stress and cytotoxicity by PCB126 in JEG-3 human choriocarcinoma cells. J. Environ. Sci. Health A 45, 932–937 (2010).

    Article  CAS  Google Scholar 

  9. Zhao, M.R. et al. Dual effect of transforming growth factor b1 on cell adhesion and invasion in human placenta trophoblast cells. Reproduction 132, 333–341 (2006).

    Article  CAS  Google Scholar 

  10. Lin, P. et al. Fbxw8 is involved in the proliferation of human choriocarcinoma JEG-3 cells. Mol. Biol. Rep. 38, 1741–1747 (2011).

    Article  CAS  Google Scholar 

  11. Nelissen, E.C., van Montfoort, A.P., Dumoulin, J.C. & Evers, J.L. Epigenetics and the placenta. Hum. Reprod. Update. 17, 397–417 (2011).

    Article  CAS  Google Scholar 

  12. Cross, J.C. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin. Genet. 64, 96–103 (2003).

    Article  CAS  Google Scholar 

  13. Fisher, S.J. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod. Biol. Endocrinol. 2, 53 (2004).

    Article  Google Scholar 

  14. Gluckman, P.D. & Hanson, M.A. Maternal constraint of fetal growth and its consequences. Semin. Fetal Neonatal Med. 9, 419–425 (2004).

    Article  Google Scholar 

  15. Eriksson, J.G., Forsen, T.J., Osmond, C. & Barker, D.J. Pathways of infant and childhood growth that lead to type 2 diabetes. Diabetes Care 26, 3006–3010 (2003).

    Article  Google Scholar 

  16. Ross, M.G. & Baell, M.H. Adult sequelae of intrauterine growth restriction. Semin Perinatol. 32, 213–218 (2008).

    Article  Google Scholar 

  17. Yung, H.W. et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am. J. Pathol. 173, 451–462 (2008).

    Article  CAS  Google Scholar 

  18. Hafner, E. et al. Placental growth from the first to the second trimester of pregnancy in SGA-foeluses and preeclamptic pregnancies compared to normal foetuses. Placenta 24, 336–342 (2003).

    Article  CAS  Google Scholar 

  19. Bernstein, I.M. et al. Morbidity and mortality among very-low-birth-weight neonatas with intrauterine growth restriction. The Vermont Oxford Network. Am. J. Obstet. Gynecol. 182, 198–206 (2000).

    Article  CAS  Google Scholar 

  20. Ornoy, A. Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reprod. Toxicol. 28, 1–10 (2009).

    Article  CAS  Google Scholar 

  21. Kostrouchová, M., Kostrouch, Z., Kostrouchová, M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia. Biol. 53, 37–49 (2007).

    Google Scholar 

  22. Bailey, D.N. & Briggs, J.R. Valproic acid binding to human serum and human placenta in vitro. Ther. Drug. Monit. 27, 375–377 (2005).

    Article  CAS  Google Scholar 

  23. Koren, G. & Kennedy, D. Safe use of valproic acid during pregnancy. Can. Fam. Physician. 45, 1451–1453 (1999).

    CAS  Google Scholar 

  24. Frederich, M., Zhang, L. & Balschi, J.A. Hypoxia and AMP independently regulate AMP-activated protein kinase activity in heart. Am. J. Physiol. Heart. Circ. Physiol. 288, 2412–2421 (2005).

    Article  Google Scholar 

  25. Gallagher, H.C. et al. Valproate activates phophodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol. Teratol. 26, 73–81 (2003).

    Article  Google Scholar 

  26. Martin, M.L. & Regan, C.M. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 554, 223–228 (1991).

    Article  CAS  Google Scholar 

  27. Fingar, D.C. et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1 /eIF4E. Genes Dev. 16, 1472–1487 (2002).

    Article  CAS  Google Scholar 

  28. Neufeld, T.P. & Edgart, B.A. Connections between growth and the cell cycle. Curr. Opin. Cell Biol. 10, 784–790 (1998).

    Article  CAS  Google Scholar 

  29. Roos, S., Powell, T.L. & Jansson, T. Placental mTOR links maternal nutrient availability to fetal growth. Biochem. Soc. Trans. 37, 295–298 (2009).

    Article  CAS  Google Scholar 

  30. Wen, H.Y., Abbasi, S., Kellems, R.E. & Xia, Y. mTOR: a placental growth signaling sensor. Placenta 26(Suppl A), S63–S69 (2005).

    Article  Google Scholar 

  31. Gwinn, D.M. et al. AMPK-phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214–226 (2008).

    Article  CAS  Google Scholar 

  32. Hardie, D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774–785 (2007).

    Article  CAS  Google Scholar 

  33. Hardie, D.G., Scott, J.W., Pan, D.A. & Hudson, E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546, 113–120 (2003).

    Article  CAS  Google Scholar 

  34. Lin, J.N. et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J. Agric. Food Chem. 58, 1584–1592 (2010).

    Article  CAS  Google Scholar 

  35. Kim, D.H. et al. GL, a positive regulator for the rapamycin-sensitive pathway required for the nutrientsensitive interaction between raptor and mTOR. Mol. Cell. 11, 895–904 (2003).

    Article  CAS  Google Scholar 

  36. Faiyre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discor. 5, 671–688 (2006).

    Article  Google Scholar 

  37. Inoki, K. et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955–968 (2006).

    Article  CAS  Google Scholar 

  38. Kim, D. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163–175 (2002).

    Article  CAS  Google Scholar 

  39. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Food and Nutrition, Eulji University, 212 Yangji-Dong, Sujueong-Gu, Seongnam-Si, Gyeonggi-Do, 461-713, Korea

    Youn-Jung Kim

  2. Cellular and Molecular Toxicology Laboratory, Center for Integrated Risk Research, Korea Institute of Science & Technology, P.O. Box 131, Cheongryang, Seoul, 130-650, Korea

    Jina Lee, Mi-Kyung Song & Jae-Chun Ryu

  3. Department of Marine Sciences, Incheon National University, 12-1 Songdo-dong, Yeonsu-gu, Incheon, 406-840, Korea

    Taejun Han

Authors
  1. Youn-Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jina Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mi-Kyung Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taejun Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae-Chun Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae-Chun Ryu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, YJ., Lee, J., Song, MK. et al. Valproic acid inhibits cell size and cell proliferation by AMPK-mediated mTOR signaling pathway in JEG-3 cells. BioChip J 7, 267–277 (2013). https://doi.org/10.1007/s13206-013-7310-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13206-013-7310-9

Keywords

Search

Navigation